Latest news and press releases about Solid Biosciences Inc. (SLDB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD.
Price
| Price | $8.72 |
| Market Cap | $858M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.35 |
| EV / EBITDA | -4.09 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -72.28% |
| Return on Invested Capital | -53.81% |
| Return on Assets | -49.24% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANNX · AURA · AUTL · BNTC · DSGN · LBRX · NMRA
Explore sector: Healthcare · Biotechnology
More sections of SLDB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks